Cantor Fitzgerald restated their overweight rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2022 earnings at ($0.69) EPS and FY2023 earnings at ($0.76) EPS.
Separately, StockNews.com started coverage on shares of Corvus Pharmaceuticals in a report on Friday, July 1st. They issued a sell rating on the stock.
Corvus Pharmaceuticals Trading Down 1.4 %
CRVS opened at $0.78 on Wednesday. The company has a 50 day moving average of $0.96 and a 200 day moving average of $1.17. The company has a market cap of $36.31 million, a PE ratio of -0.97 and a beta of 0.90. Corvus Pharmaceuticals has a 12 month low of $0.75 and a 12 month high of $8.11.
Institutional Investors Weigh In On Corvus Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Corvus Pharmaceuticals by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,267,752 shares of the company’s stock worth $2,079,000 after buying an additional 36,002 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Corvus Pharmaceuticals by 6.9% in the second quarter. Renaissance Technologies LLC now owns 962,932 shares of the company’s stock worth $953,000 after buying an additional 61,800 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Corvus Pharmaceuticals by 38.3% in the fourth quarter. Point72 Asset Management L.P. now owns 795,000 shares of the company’s stock worth $1,916,000 after buying an additional 220,000 shares in the last quarter. Acadian Asset Management LLC raised its position in Corvus Pharmaceuticals by 72.6% during the first quarter. Acadian Asset Management LLC now owns 140,118 shares of the company’s stock valued at $228,000 after purchasing an additional 58,952 shares in the last quarter. Finally, State Street Corp raised its position in Corvus Pharmaceuticals by 12.2% during the first quarter. State Street Corp now owns 112,603 shares of the company’s stock valued at $185,000 after purchasing an additional 12,203 shares in the last quarter. Hedge funds and other institutional investors own 55.02% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.
- Get a free copy of the StockNews.com research report on Corvus Pharmaceuticals (CRVS)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.